Cover Image
市場調查報告書

Beijing Minhai Biotechnology Co., Ltd :產品平台分析

Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 315709
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
Beijing Minhai Biotechnology Co., Ltd :產品平台分析 Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2015
出版日期: 2015年04月22日 內容資訊: 英文 46 Pages
簡介

Beijing Minhai Biotechnology Co., Ltd是研究開發、產品化傳染病的預防和治療用疫苗,以有助於人們健康為目標的生物科技企業。

本報告提供Beijing Minhai Biotechnology Co., Ltd的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Beijing Minhai Biotechnology Co., Ltd的基本資料

  • Beijing Minhai Biotechnology Co., Ltd概要
  • 主要資訊
  • 企業資料

Beijing Minhai Biotechnology Co., Ltd :R&D概要

  • 主要的治療範圍

Beijing Minhai Biotechnology Co., Ltd :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Beijing Minhai Biotechnology Co., Ltd :開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Beijing Minhai Biotechnology Co., Ltd :藥物簡介

  • pneumococcal polysaccharide vaccine (23-valent)
  • hepatitis A vaccine
  • hepatitis B vaccine
  • meningococcal conjugate vaccine serogroups A, C, Y and W135
  • cholera vaccine (trivalent)
  • diphtheria + tetanus + pertussis (acellular) vaccine
  • haemophilus influenzae conjugate vaccine type B
  • hepatitis A + hepatitis B vaccine
  • influenza vaccine (split virion)
  • meningococcal conjugate vaccine (tetravalent)
  • meningococcal polysaccharide vaccine (tetravalent)
  • pneumococcal conjugate vaccine 13-valent
  • rabies vaccine MRC-5
  • enterovirus 71 vaccine
  • herpes vaccine
  • human papillomavirus vaccine (tetravalent)
  • influenza vaccine H1N1
  • meningococcal vaccine serogroup B
  • pneumococcal conjugate vaccine (15-valent)
  • rotavirus vaccine (pentavalent)

Beijing Minhai Biotechnology Co., Ltd :開發平台分析

  • 各給藥途徑
  • 各分子類型

Beijing Minhai Biotechnology Co., Ltd :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06908CDB

Summary

Global Markets Direct's, 'Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2015', provides an overview of the Beijing Minhai Biotechnology Co., Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Beijing Minhai Biotechnology Co., Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Beijing Minhai Biotechnology Co., Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Beijing Minhai Biotechnology Co., Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Beijing Minhai Biotechnology Co., Ltd's pipeline products

Reasons to buy

  • Evaluate Beijing Minhai Biotechnology Co., Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Beijing Minhai Biotechnology Co., Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Beijing Minhai Biotechnology Co., Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Beijing Minhai Biotechnology Co., Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Beijing Minhai Biotechnology Co., Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Beijing Minhai Biotechnology Co., Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Beijing Minhai Biotechnology Co., Ltd Snapshot
    • Beijing Minhai Biotechnology Co., Ltd Overview
    • Key Information
    • Key Facts
  • Beijing Minhai Biotechnology Co., Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Products Glance
    • Beijing Minhai Biotechnology Co., Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Beijing Minhai Biotechnology Co., Ltd - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Beijing Minhai Biotechnology Co., Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Beijing Minhai Biotechnology Co., Ltd - Drug Profiles
    • pneumococcal polysaccharide (23-valent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (acellular) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • haemophilus influenzae [serotype B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal [serogroups A, C, Y and W135] (tetra valent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal polysaccharide [serogroups A, C, Y and W135] (tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rabies vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cholera (trivalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A + hepatitis B vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis B vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza (split virion) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pneumococcal (13-valent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enterovirus 71 vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes zoster vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human papillomavirus (tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [H1N1] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • measles + rubella + varicella vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal [serogroup B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mumps vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rotavirus (pentavalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • varicella vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Analysis
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Products by Route of Administration
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Products by Molecule Type
  • Beijing Minhai Biotechnology Co., Ltd - Dormant Projects
  • Beijing Minhai Biotechnology Co., Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Beijing Minhai Biotechnology Co., Ltd, Key Information
  • Beijing Minhai Biotechnology Co., Ltd, Key Facts
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Indication, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Stage of Development, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Monotherapy Products in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Combination Treatment Modalities in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Partnered Products in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Partnered Products/ Combination Treatment Modalities, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pre-Registration, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Phase III, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Phase I, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Preclinical, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Route of Administration, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Molecule Type, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Dormant Developmental Projects,2015

List of Figures

  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Top 10 Indication, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Stage of Development, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Monotherapy Products in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Combination Treatment Modalities in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Top 10 Route of Administration, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Top 10 Molecule Type, 2015
Back to Top